B-CELL LYMPHOMA

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell lymphoma has returned or not responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs t…

This early-phase study is testing a new version of CAR-T cell therapy called U01 (ssCART-19) in adults and children (ages 2-75) with B-cell lymphoma that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab …

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This study is testing a combination of two immunotherapy drugs for people with a type of blood cancer called large B-cell lymphoma that has returned or didn't respond to first treatment. The goal is to see if using a personalized cell therapy (axi-cel) together with a targeted an…

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is testing whether combining two drugs—mosunetuzumab and lenalidomide—works better than current treatments for people newly diagnosed with certain slow-growing lymphomas. The trial will enroll 52 adults who haven't had any previous cancer treatment. Doctors will adjust…

This study is testing a new cell therapy for patients whose blood cancers have returned or not responded to standard treatments. Researchers are giving patients specially engineered immune cells, called NK cells, which come from donated cord blood. The goal is to see if these mod…

This study is testing a combination of existing drugs to treat a dangerous immune system overreaction called HLH in people with B-cell lymphoma. The goal is to control this severe complication and improve survival. About 40 patients will receive the drug combination for 4 weeks, …

This early study is testing a new treatment called LCAR02, a gene injection designed to target CD19 on cancer cells, in up to 18 adults with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see…

This study is testing whether combining two existing drugs—pembrolizumab and ATRA—can help control Hodgkin lymphoma or B-cell non-Hodgkin lymphoma that has returned or stopped responding to other treatments. It will enroll about 24 adults to see if the combination is safe and can…

This study is testing a new type of CAR-T cell therapy for adults with a specific, difficult-to-treat form of B-cell lymphoma. The cancer in these patients does not have the CD19 marker, making it unresponsive to many existing CAR-T treatments. The main goal of this early-phase t…

This study is testing whether a combination of four different immunotherapy and targeted therapy drugs can help control two types of B-cell lymphoma that have returned after prior treatment. It will enroll about 36 adults whose lymphoma has progressed despite at least one previou…

This study is testing the safety and early effectiveness of a new drug, BGB-16673, when given with other cancer medicines. It is for people whose B-cell cancers, like certain lymphomas, have returned or stopped responding to previous treatments. The trial will test four different…

This study is testing whether combining two existing drugs—rituximab and zanubrutinib—is safe and effective for people with untreated slow-growing B-cell lymphomas. It will enroll 43 adults with either follicular lymphoma or marginal zone lymphoma who need systemic treatment. Res…

This study aims to monitor the long-term safety of the drug pirtobrutinib in people with previously treated blood cancers like chronic lymphocytic leukemia and lymphoma. It is only open to a small group of 13 people who are already benefiting from the drug in a previous trial. Pa…

This study is testing a new, experimental CAR-T cell therapy designed to fight two targets (CD19 and CD22) on cancer cells at once. It is for children and young adults (ages 3-39) whose B-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. Doctors …

This early-phase study is testing a new type of cell therapy called universal CAR-T (UWD-CD19) for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to standard treatments. The goal is to see if this 'off-the-shelf' therapy, made from donor…

This study aims to see if adding a new drug called sonrotoclax to an existing drug (zanubrutinib) works better than zanubrutinib alone for adults whose mantle cell lymphoma has returned or stopped responding to prior treatments. It will involve about 300 participants and directly…

This is a first-in-human safety study testing a new personalized cell therapy called CLIC-2201. It is for adults and children with B-cell blood cancers (like leukemia and lymphoma) that have returned or not responded to other treatments. The main goal is to find the safest and mo…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…